ArticleThe Journal of investigative dermatology2017
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done.
Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Necroptosis in SJS/TEN:Current issues in molecular biology · 2026Article
- Stevens-Johnson syndrome and toxic epidermal necrolysis in pregnancy.The British journal of dermatology · 2026Article
- A case of toxic epidermal necrolysis in an elderly female patient.SAGE open medical case reports · 2026Article
- The Potential Roles of IL-1β, IL-6, and RIPK3 in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Diagnostics (Basel, Switzerland) · 2025Article
- Stevens-Johnson syndrome induced by Sintilimab: a case report and literature review.Frontiers in oncology · 2025Article
- Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology.Frontiers in pharmacology · 2025Article
- Deregulated Long Non-Coding RNAs (lncRNA) as Promising Biomarkers in Hidradenitis Suppurativa.Journal of clinical medicine · 2024Article
- Effect of Early Cyclosporine Treatment on Survival in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Cureus · 2024Article
- Review
- The Role of NLRP3 Inflammasome in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Medical research archives · 2024Article
- A Rare Case of Severe Stevens-Johnson Syndrome Triggered by Topical Ofloxacin.The American journal of case reports · 2023Article
- Allopurinol-Induced Uncommon Dermatological Emergency of Toxic Epidermal Necrolysis (TEN).Cureus · 2023Article
- Multidisciplinary Treatment in Toxic Epidermal Necrolysis.International journal of environmental research and public health · 2023Review
- Hypersensitivity to Biological Treatments in Juvenile Idiopathic Arthritis: How Should It Be Managed?Journal of clinical medicine · 2022Review
- Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity.Journal of biomedical science · 2022Article
- IL-15/IL-15Rα in SJS/TEN: Relevant Expression ofBiomedicines · 2022Article
- Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics.Frontiers in pharmacology · 2022Review
- Case report: Development of vanishing bile duct syndrome in Stevens-Johnson syndrome complicated by hemophagocytic lymphohistiocytosis.Frontiers in medicine · 2022Article
- Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs.Frontiers in medicine · 2022Article
- Toxic epidermal necrosis associated with phenobarbitone: a case report and brief review of the literatures.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Although rare, Stevens-Johnson syndrome and toxic epidermal necrolysis remain among the most devastating of acute conditions involving the skin. In the past 30 years, tremendous progress has been made in understanding the causes and pathobiology of this often life-threatening condition. Su et al demonstrate associations between IL 15 serum levels and the outcome of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Their findings provide ideas for further investigations that may help us better understand the role of cytokines in this T-cell mediate disease and provides clues to possible new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.